Loading...
 
Back to the list
Mediterr J Rheumatol 2017;28(1):13-9
Article Links
Interferon targeted therapies in systemic lupus erythematosus
Durga Prasanna Misra1, Vir Singh Negi2
Authors Information

1: Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India

2: Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Puducherry, India

Keywords: Type I interferon, systemic lupus erythematosus, sifalimumab, rontalizumab, interferon alpha kinoid, plasmacytoid dendritic cell
References
  1. Pestka S, Krause C D, Walter M R. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004;202:8-32.
  2. James J A, Kaufman K M, Farris A D, Taylor-Albert E, Lehman T J, Harley J B. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997;100:3019-3026.
  3. Harley J B, Harley I T, Guthridge J M, James J A. The curiously suspicious: a role for Epstein-Barr virus in lupus. Lupus 2006;15:768-77.
  4. Perry D, Sang A, Yin Y, Zheng Y Y, Morel L. Murine models of systemic lupus erythematosus. J Biomed Biotechnol 2011;2011:271694.
  5. Niewold T B. Advances in lupus genetics. Curr Opin Rheumatol 2015;27:440-7.
  6. Crow Y J. Type I interferonopathies: mendelian type I interferon up-regulation. Curr Opin Immunol 2015;32:7-12.
  7. Shao W H, Cohen P L. Disturbances of apoptotic cell clearance in systemic lupus erythematosus. Arthritis Res Ther 2011;13:202.
  8. Fransen J H, van der Vlag J, Ruben J, Adema G J, Berden J H, Hilbrands L B. The role of dendritic cells in the pathogenesis of systemic lupus erythematosus. Arthritis Res Ther 2010;12:207.
  9. Holl E K, Shumansky K L, Borst L B, Burnette A D, Sample C J, Ramsburg E A, et al. Scavenging nucleic acid debris to combat autoimmunity and infectious disease. Proc Natl Acad Sci U S A 2016;113:9728-33.
  10. Rowland S L, Riggs J M, Gilfillan S, Bugatti M, Vermi W, Kolbeck R, et al. Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model. J Exp Med 2014;211:1977-91.
  11. Nurmohamed M T, Heslinga M, Kitas G D. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol 2015;11:693-704.
  12. Thacker S G, Zhao W, Smith CK, Luo W, Wang H, Vivekanandan-Giri A, et al. Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum 2012;64:2975-85.
  13. Higgs B W, Liu Z, White B, Zhu W, White W I, Morehouse C, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011;70:2029-36.
  14. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm398682.htm [accessed on 15 November 2016].
  15. Willis R, Seif A M, McGwin G, Jr., Martinez-Martinez L A, Gonzalez E B, Dang N, et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus 2012;21:830-5.
  16. Gasparyan A Y, Ayvazyan L, Blackmore H, Kitas G D. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 2011;31:1409-17.
  17. Bennett L, Palucka A K, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23.
  18. Baechler E C, Batliwalla F M, Karypis G, Gaffney P M, Ortmann W A, Espe K J, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003;100:2610-15.
  19. Kennedy W P, Maciuca R, Wolslegel K, Tew W, Abbas A R, Chaivorapol C, et al. Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE. Lupus Sci Med 2015;2:e000080.
  20. Morimoto A M, Flesher D T, Yang J, Wolslegel K, Wang X, Brady A, et al. Association of endogenous anti-interferon-alpha autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:2407-15.
  21. Merrill J T, Wallace D J, Petri M, Kirou K A, Yao Y, White W I, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 2011;70:1905-13.
  22. Petri M, Wallace D J, Spindler A, Chindalore V, Kalunian K, Mysler E, et al. Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 2013;65:1011-21.
  23. Khamashta M, Merrill J T, Werth V P, Furie R, Kalunian K, Illei G G, et al. Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016;75:1909-16.
  24. McBride J M, Jiang J, Abbas A R, Morimoto A, Li J, Maciuca R, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 2012;64:3666-76.
  25. Kalunian K C, Merrill J T, Maciuca R, McBride J M, Townsend M J, Wei X, et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis 2016;75:196-202.
  26. Navarra S V, Guzman R M, Gallacher A E, Hall S, Levy R A, Jimenez R E, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
  27. Furie R, Petri M, Zamani O, Cervera R, Wallace D J, Tegzova D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.
  28. Zagury D, Le Buanec H, Mathian A, Larcier P, Burnett R, Amoura Z, et al. IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci U S A 2009;106:5294-9.
  29. Mathian A, Amoura Z, Adam E, Colaone F, Hoekman M F, Dhellin O, et al. Active immunisation of human interferon alpha transgenic mice with a human interferon alpha Kinoid induces antibodies that neutralise interferon alpha in sera from patients with systemic lupus erythematosus. Ann Rheum Dis 2011;70:1138-43.
  30. Lauwerys B R, Hachulla E, Spertini F, Lazaro E, Jorgensen C, Mariette X, et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum 2013;65:447-56.
  31. Wang B, Higgs B W, Chang L, Vainshtein I, Liu Z, Streicher K, et al. Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-alpha receptor antibody. Clin Pharmacol Ther 2013;93:483-92.
  32. Du P, Xu L, Qiu W, Zeng D, Yue J, Wang S, et al. A fully human monoclonal antibody with novel binding epitope and excellent neutralizing activity to multiple human IFN-alpha subtypes: A candidate therapy for systemic lupus erythematosus. MAbs 2015;7:969-80.
  33. Peng L, Oganesyan V, Wu H, Dall'Acqua W F, Damschroder M M. Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-alpha receptor 1 antibody. MAbs 2015;7:428-39.
  34. Sacre K, Criswell L A, McCune J M. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther 2012;14:R155.
  35. Wang J, Lau K Y, Jung J, Ravindran P, Barrat F J. Bruton's tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells. Eur J Immunol 2014;44:1130-6.
  36. Pellerin A, Otero K, Czerkowicz J M, Kerns H M, Shapiro R I, Ranger A M, et al. Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms. EMBO Mol Med 2015;7:464-76.
  37. Dillmann C, Ringel C, Ringleb J, Mora J, Olesch C, Fink A F, et al. S1PR4 Signaling Attenuates ILT 7 Internalization To Limit IFN-alpha Production by Human Plasmacytoid Dendritic Cells. J Immunol 2016;196:1579-90.
  38. Rommler F, Hammel M, Waldhuber A, Muller T, Jurk M, Uhlmann E, et al. Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells. PLoS One 2015;10:e0116703.
  39. Alexander T, Sarfert R, Klotsche J, Kuhl A A, Rubbert-Roth A, Lorenz H M, et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 2015;74:1474-8.
  40. Zhan Y, Carrington E M, Ko H J, Vikstrom I B, Oon S, Zhang J G, et al. Bcl-2 antagonists kill plasmacytoid dendritic cells from lupus-prone mice and dampen interferon-alpha production. Arthritis Rheumatol 2015;67:797-808.
  41. Huang X, Xie Z, Liu F, Han C, Zhang D, Wang D, et al. Dihydroartemisinin inhibits activation of the Toll-like receptor 4 signaling pathway and production of type I interferon in spleen cells from lupus-prone MRL/lpr mice. Int Immunopharmacol 2014;22:266-72.